HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DEA Exclusion From 11th Report On Carcinogens Advised By NTP Panel

This article was originally published in The Rose Sheet

Executive Summary

Existing data suggesting diethanolamine may pose a safety risk do not meet National Toxicology Program criteria to be designated a possible human carcinogen, an NTP Board of Scientific Counselors subcommittee concluded at a meeting in Bethesda, Md. Nov. 19

You may also be interested in...



Lead Compounds “Reasonably Anticipated” To Be Carcinogenic – NTP Panel

Lead and all lead compounds should be included in the 11th Report on Carcinogens, a National Toxicology Program Board of Scientific Counselors RoC subcommittee concluded at an Oct. 14 meeting in Washington, D.C

Lead Compounds “Reasonably Anticipated” To Be Carcinogenic – NTP Panel

Lead and all lead compounds should be included in the 11th Report on Carcinogens, a National Toxicology Program Board of Scientific Counselors RoC subcommittee concluded at an Oct. 14 meeting in Washington, D.C

TEA Carcinogenic Link Suggested By Two Year NTP Study

Triethanolamine demonstrated "some evidence" of carcinogenic activity in a two-year dermal study of female B6C3F1 mice and "equivocal evidence" of carcinogenic activity in male mice, the National Toxicology Program states in a 1draft technical report on the ingredient

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS010772

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel